CytoMed Therapeutics Limited (GDTC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
CytoMed Therapeutics Limited has successfully dosed the first patient in its groundbreaking Phase I clinical trial, ANGELICA, which explores the potential of allogeneic CAR-gamma delta T cell therapy for treating advanced cancers. This innovative approach aims to improve accessibility and reduce costs by using donor-derived cells, marking a significant milestone for the company. Investors may find this development intriguing as it could reshape the landscape of cancer treatment.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.
